Therapeutic area intelligence for Clostridioides difficile with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

AstraZeneca →

Assets

AZD5148 →

Recent signals(1)

ClinicalAugust 13, 2026

AstraZeneca initiates trial for AZD5148 to prevent recurrent Clostridioides difficile infection

AstraZeneca is evaluating AZD5148 for preventing recurrence of Clostridioides difficile infection in adults.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.